Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma：A Single-Arm Phase 2 Clinical Trial

NCT05947201 is registered in ClinicalTrials.gov with Weijia Fang, MD as lead sponsor.

NCT NCT05947201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma：A Single-Arm Phase 2 Clinical Trial
Lead sponsor
Weijia Fang, MD
Phase
Phase 2
Overall status
Unknown status
Start date
May 8, 2023
Completion date
October 1, 2024
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

the efficacy and safety of therapy efficacy for locally advanced escc